Voxvoganan: First-in-Class Synthetic Antimicrobial Peptidomimetic Development Data

Voxvoganan is a synthetic antimicrobial peptidomimetic designed to mimic natural antimicrobial peptides. The dataset, authored by Wenche Stensen and last updated on 2026-04-20, describes its development, including toxicology, safety studies, and Phase 1 and 2 clinical trials. The data is stored in a CSV file with a size of 888.0 B.

Use Cases

• Study the design principles of synthetic antimicrobial peptidomimetics based on the description of mimicking natural peptides.
• Analyze the development pathway for a first-in-class drug based on the mentioned toxicology, safety, and clinical trial phases.
• Investigate potential applications for respiratory viral infection treatment based on the described therapeutic target.
• Explore the use of antimicrobial active pharmaceutical ingredients in medical devices to prevent microbial fouling, as mentioned in the description.

Strengths

• The dataset describes a specific, novel compound (Voxvoganan) with a clear first-in-class designation.
• Development details include specific milestones: toxicology studies and Phase 1 and 2 clinical trials.
• The data file is small (888.0 B), facilitating quick download and inspection.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset's scale is very small (888.0 B), suggesting limited data volume.

Provenance

Source

figshare, author Wenche Stensen

Collection Method

Likely contains data related to the compound's research and development process.

Freshness

Last updated 2026-04-20 11:35:06; freshness should be verified.